Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.55 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HTR5A | P47898 | 1/20 | 0.45 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.45 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PNMT | P11086 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31020970 | 1.00 | TAAR1 (0.55) | TAAR1SIRT2HTR2AHTR2CKDM4E | |
| Hydrochloric Acid SCHEMBL23828286 | 0.98 | TAAR1 (0.58) | TAAR1SIRT2HTR2AHTR2CKDM4E | |
| Hydrochloric Acid SCHEMBL10407659 | 0.86 | NISCH (0.55) | TAAR1SIRT2HTR2AHTR2CKDM4E | |
| SCHEMBL18345713 | 0.81 | TAAR1 (0.55) | TAAR1SIRT2HTR2AHTR2CKDM4E | |
| SCHEMBL2241341 | 0.81 | TAAR1 (0.55) | TAAR1SIRT2HTR2AHTR2CKDM4E | |
| SCHEMBL4791996 | 0.81 | TAAR1 (0.47) | TAAR1SIRT2HTR2AHTR2CKDM4E | |
| SCHEMBL28549389 | 0.78 | SMN1; SMN2 (0.50) | KDM4EPARP1CFTRALDH1A1 | |
| SCHEMBL28559488 | 0.78 | SMN1; SMN2 (0.50) | KDM4EPARP1CFTRALDH1A1 | |
| SCHEMBL2247075 | 0.78 | TAAR1 (0.49) | TAAR1SIRT2HTR2AHTR2CKDM4E | |
| SCHEMBL4793856 | 0.77 | SIRT2 (0.47) | TAAR1SIRT2HTR2AHTR2CKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3820867-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2023-09-13 | — | — | EP | disclosed |
| US-20210292324-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS | ISTITUTO GIANNINA GASLINI (IT) | 2021-09-23 | — | — | US | disclosed |
| WO-2020012427-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2020-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292324-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCB11, ABCC5 | TAAR1 3882/4885SIRT2 3850/4885HTR2A 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.